In the News
Global Alzheimer’s Platform Foundation Applauds FDA Draft Guidance to Improve Diverse Participation in Clinical Trials
Washington D.C., July 1, 2024- The Food and Drug Administration (FDA) unveiled a draft guidance document, “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies,” which is open for public comment. This draft guidance points to improving participation from people who are traditionally underrepresented in clinical trials. John Dwyer, President […]
Stroll Hyde Park Magazine: Memory Issues or Normal Signs of Aging?
Resident contributor, Dr. Susan Steen breaks down three life changes to trackto prioritize your brain health as you and your loved ones age. As people age, it’s normal to experience occasional forgetfulness, however when does ‘some’ memory loss become a bigger concern? There are three aspects of your life that you can reflect on and […]
Global Alzheimer’s Platform Foundation Welcomes Tandem Clinical Research Site to its Network
Global non-profit expands research network to the greater New Orleans areato improve access to research opportunities Washington D.C., June. 17, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming its first clinical research site from Louisiana into its network, Tandem Clinical Research of greater New Orleans. Tandem Clinical Research, a Prolerity Clinical Research Company site, advances […]
Global Alzheimer’s Platform Foundation Collaborates on First-Ever Performance Recommendations for Blood-Based Biomarker Tests
Washington D.C., June. 14, 2024- Global Alzheimer’s Platform Foundation® (GAP) proudly collaborated with The Global CEO Initiative on Alzheimer’s Disease (CEOi) to release the peer-reviewed publication of “Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease,” in Nature Reviews Neurology. Alzheimer’s blood tests have the […]
Global Alzheimer’s Platform Foundation Applauds the FDA’s Acceptance of the Subcutaneous Version of Leqembi
Washington D.C., June.10, 2024- Global Alzheimer’s Platform Foundation® (GAP) –applauds the U.S. Food and Drug Administration (FDA)’s acceptance of Eisai’s application for the subcutaneous maintenance dosing of Leqembi. With an action date set for January 25, 2025, this autoinjector will be used for weekly maintenance dosing and stands to reduce the burden on patients who are eligible to receive this disease-modifying therapy, as it can be used […]
Impact OC: Alzheimer’s Research
Global Alzheimer’s Platform Foundation 2023 National Citizen Scientist Champion Award recipient Jeannie Weiss and Syrentis Clinical Research Vice President/Director of Clinical Operations Dr. Lorrie Bisesi join to discuss Alzheimer’s #octalkradio
First-of-its-Kind Bio-Hermes Challenge Sparks Global Interest for Novel Research
Support from Scottish Parliament Underscores Its Significance Washington D.C., May 30, 2024- The Global Alzheimer’s Platform Foundation® (GAP) and the Scottish Funding Council’s Brain Health ARC have announced swift progress in the next steps of the Bio-Hermes Biomarker Data Challenge 2024, the research competition using the most comprehensive set of dementia biomarker data from ground-breaking […]
MarketScreener: IXICO plc Signs Contract with Global Alzheimer’s Platform Foundation to Support Bio-Hermes 2 Trial
May 23, 2024 at 02:00 am EDT IXICO plc announced that it has signed a contract with the Global Alzheimer’s Platform Foundation (GAP) to support GAP’s planned Bio-Hermes 2 trial. The contract value is worth over £1 million over a 48-month term. The Company does not expect to adjust its expectations of performance for the […]
Scottish Funding Council Guest Blog: Science as a team sport
In the hands of the SFC-funded Brain Health ARC, the Bio-Hermes dataset offers the Scottish dementia research community a platform for new ideas, collaboration and early career development. Millie Mather explains more in our latest guest blog. During my working hours, I can be identified as the sole person in the room without a PhD in science or medicine. In fact, […]
Fullerton Observer: Local Researchers Hold FREE Memory Screening for Community on Thursday, May 16
Syrentis Clinical Research will hold a free memory screening event on Thursday, May 16, for people aged 50 and above to increase awareness for early detection of memory loss and Alzheimer’s disease. In California, it is estimated that more than 690,000 people are currently living with Alzheimer’s Disease, and experts predict that this number will […]